Legend Biotech Corporation Sponsored ADR LEGN
19.11
0.05
0.26%
as of 25 Sep
- Market cap
- $3.7B
- P/E
- 0.0×
Follow LEGN
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.62 | 3.89 | 2.94 | 4.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
209.03 | (328.32) | (39.35) | (258.40) | |
P/B ratio |
5.95 | 4.00 | 3.46 | 4.39 | |
Price to Tangible BV |
5.97 | 4.01 | 3.47 | 4.40 | |
EV/Sales |
5.88 | 3.45 | 2.59 | 3.75 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(31.42) | (35.42) | (36.13) | (53.29) | |
EV/FCF |
(28.24) | (27.43) | (25.36) | (38.93) | |
Quick Ratio |
2.29 | 1.51 | 1.64 | 2.39 | |
Current Ratio |
2.86 | 1.96 | 2.13 | 3.04 | |
Net Debt/EBITDA |
18.29 | 62.74 | 14.47 | (11.99) | |
Debt/Assets |
18.38% | 18.41% | 16.66% | 8.93% | |
Debt/Equity |
0.31 | 0.32 | 0.27 | 0.13 | |
Asset Turnover |
0.53 | 0.60 | 0.71 | 0.74 | |
Operating CF/Net income |
(0.73) | 0.40 | 1.57 | (0.63) | |
Capex/Depreciation |
(0.83) | (1.03) | (0.48) | (0.64) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
41.55% | 33.07% | 28.09% | 24.77% | |
Selling, General and Administrative Expense of Revenue |
32.07% | 32.98% | 29.53% | 24.88% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.09 | 0.13 | 0.14 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.99%) | (7.41%) | (7.49%) | (1.72%) | |
Free Cash Flow Yield |
(3.14%) | (3.23%) | (3.48%) | (2.27%) | |
Revenue per Share |
1.47 | 1.66 | 1.65 | 2.07 | |
Operating CF per Share |
0.16 | (0.07) | (0.46) | (0.11) | |
Capex per Share |
(0.03) | (0.07) | (0.04) | (0.04) | |
Free Cash Flow per Share |
0.13 | (0.13) | (0.50) | (0.15) | |
Cash per Share |
5.38 | 5.15 | 4.51 | 5.16 | |
Shareholders Equity per Share |
5.48 | 5.44 | 5.23 | 6.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.48 | 5.44 | 5.23 | 6.58 | |
Free Cash Flow |
23.77 | (24.57) | (92.60) | (28.40) | |
Working Capital |
808.43 | 610.70 | 573.60 | 823.80 | |
Capital Expenditures |
(5.03) | (12.37) | (7.50) | (7.50) | |
Net Current Asset Value |
540.32 | 515.50 | 453.70 | 706.10 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.04 | 0.02 | 0.02 | |
Net Profit Margin |
(14.57%) | (10.02%) | (17.80%) | 8.57% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.97 | 9.75 | 1.03 | — | |
Average Payables |
64.68 | 60.80 | 66.22 | 76.33 | |
Average Inventory |
26.37 | 27.95 | 34.02 | 38.54 | |
Average Assets |
1,724.39 | 1,701.95 | 1,606.17 | 1,720.41 | |
Average Common Equity |
1,063.68 | 1,021.35 | 992.72 | 1,132.57 |
Columns are period end dates